Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AVC-S-101
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : EQT Life Sciences
Deal Size : $50.0 million
Deal Type : Financing
Avidicure Launches with $50M Seed Round to Develop Cancer Antibody Therapy
Details : The financing aims to advance the clinical development of lead product AVC-S-101, a TROP2-targeting booster being developed for non-small cell lung cancer and multiple other cancer indications.
Product Name : AVC-S-101
Product Type : Antibody
Upfront Cash : Undisclosed
April 24, 2025
Lead Product(s) : AVC-S-101
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : EQT Life Sciences
Deal Size : $50.0 million
Deal Type : Financing